Physician profile
Sheng-Han Kuo
NPI 1427200195
$657,377.70
in general payments reported to CMS, 2019-2025
18 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $2,018 · 2021: $50K · 2022: $126K · 2023: $125K · 2024: $119K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $309K · Consulting Fee: $110K · Travel and Lodging: $37K · Food and Beverage: $10K · Honoraria: $9,276 · Education: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $309,294.34 |
| Consulting Fee | $110,045.66 |
| Travel and Lodging | $37,199.29 |
| Food and Beverage | $10,340.91 |
| Honoraria | $9,276.00 |
| Education | $1,668.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $409,743.68 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $202,453.47 | 2023-2025 | Skyclarys, Skyclarys |
| Kyowa Kirin, INC. | $13,223.85 | 2020-2025 | Nourianz |
| Amneal Pharmaceuticals LLC | $7,759.75 | 2024-2025 | Ongentys, Ongentys 50mg Capsules 30, Crexont |
| Sage Therapeutics, LLC | $4,978.07 | 2020-2024 | |
| H. Lundbeck A S | $4,440.32 | 2024-2025 | |
| Ucb Sa | $4,381.67 | 2022 | |
| Sanofi US Services INC. | $3,860.00 | 2024 | |
| Genzyme Corporation | $2,572.00 | 2024 | |
| Acadia Pharmaceuticals INC | $1,380.02 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $995.00 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $700.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $686.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $57.30 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $21.44 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheng-Han Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.